Common use of UT Agreement Clause in Contracts

UT Agreement. 1.1 Capitalized terms used in this Section 1 but not defined in the Agreement shall have the meanings given to them in the UT Agreement. 1.2 The rights granted by MedImmune to Kolltan as sublicensee under the UT Agreement are subject to the rights, conditions and limitations imposed by United States law on inventions and discoveries conceived or first actually reduced to practice during the course of research funded by a United States federal agency, as described in the first Section 3.2 of the UT Agreement. 1.3 MedImmune is indirectly obligated to require Kolltan to take steps as necessary and solely as they relate to Kolltan’s activities under the Agreement to enable MedImmune to perform its obligations under the following provisions of the UT Agreement: 1.3.1 first two sentences of Section 5.3; 1.3.2 the reporting obligations described in Section 5.4; 1.3.3 the second, third and fourth sentences of Section 5.5; 1.3.4 Section 5.7; and 1.3.5 the first and third sentences of Section 7.1. The Parties acknowledge and agree that (a) the Agreement includes provisions whereby Kolltan is bound to take such steps, and (b) the foregoing provisions of the UT Agreement include all the terms and conditions of the UT Agreement that are applicable to Kolltan as sublicensee under the UT Agreement.

Appears in 3 contracts

Sources: License and Option Agreement (Celldex Therapeutics, Inc.), License and Option Agreement (Kolltan Pharmaceuticals Inc), License and Option Agreement (Kolltan Pharmaceuticals Inc)